# Glucotrack, Inc. (GCTK) · Edgar & Edgarette company card

> Glucotrack (GCTK) grew revenue 378% in FY2019 to $0 million, operating margin 1686% against a 1.2% median for surgical & medical instruments & apparatus, equity -129% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1506983 · fiscal year ended 2019-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/GCTK) · [JSON](https://www.pops4.com/boards/company/GCTK.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $208,000 |
| Revenue growth, 1 year | 378.3% |
| Revenue growth per year | 9.8% |
| Operating margin | 1685.6% (prior year -15035.4%) |
| Net margin | 1690.4% |
| Operating cash flow | −$4M |
| Capital spending | $23,000 |
| Free cash flow | −$4M |
| Cash | $419,000 |
| Long-term debt | — |
| Total assets | $1M |
| Total equity | −$1M |
| Equity ÷ assets | -128.8% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -258.19 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$15.2M in FY2025); revenue is hard to predict: its 80% range is ±67%

## Edgarette's reading

Exposure: revenue $208K (FY2019). Experience: revenue up 378.3% on the year, up 9.8% a year over 4 years; operating margin 1685.6%, up from -15035.4%. Soundness: equity -128.8% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $250K and $1.3M next year (method v4.1: its own 2-year record of growth weighed at 25% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $224K to $1.4M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 1685.6% against a 1.2% median; growth 378.3% against 11.6%.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-10-29 ([filing](https://www.sec.gov/Archives/edgar/data/1506983/000149315226049299/0001493152-26-049299-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-09-18 ([filing](https://www.sec.gov/Archives/edgar/data/1506983/000149315226043389/0001493152-26-043389-index.htm))

## Recent filings

- 8-K · filed 2026-10-29 · 3.01 Notice of Delisting or Failure to Satisfy a Listing Rule · [filing](https://www.sec.gov/Archives/edgar/data/1506983/000149315226049299/0001493152-26-049299-index.htm)
- 8-K · filed 2026-10-28 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1506983/000149315226048981/0001493152-26-048981-index.htm)
- 8-K · filed 2026-10-22 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1506983/000149315226048139/0001493152-26-048139-index.htm)
- 8-K · filed 2026-10-19 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1506983/000149315226047582/0001493152-26-047582-index.htm)
- 8-K · filed 2026-09-28 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1506983/000149315226044657/0001493152-26-044657-index.htm)
- 8-K · filed 2026-09-24 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1506983/000149315226044182/0001493152-26-044182-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001506983.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1506983

## Cite

POPS4, Edgar & Edgarette: Glucotrack, Inc. (GCTK) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/GCTK. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2019, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.